Efficacy of humanlike Augmentin SR (2000/125 mg) twice daily treatment on Haemophilus influenzae experimental pneumonia in rabbits

References

• Bryce J, Boschi-Pinto C, Shibuya K, Black RE. WHO estimates of the causes of death in children. Lancet 2005; 365: 1147–52
   PubMed Web of Science ®Google Scholar
• World Health Organization. Child health epidemiology reference group. www.who.int/child.adolescent/New_publications/Overview/CHERG_Meeting_Fe 2002.pdf. 2002.
   Google Scholar
• Shann F. Bacterial pneumonia: commoner than perceived. Lancet 2001; 357: 2070–2
   PubMed Web of Science ®Google Scholar
• Shann F. Haemophilus influenzae pneumonia: type b or non-type b?. Lancet 1999; 354: 1488–90
   PubMed Web of Science ®Google Scholar
• Peltola H. Spectrum and burden of severe Haemophilus influenzae type b diseases in Asia. Bull World Health Organ 1999; 77: 878–87
   PubMed Web of Science ®Google Scholar
• Swingler, G, Fransman, D, Hussey, G. Conjugate vaccines for preventing Haemophilus influenzae type b infections. Cochrane Database Syst Rev 2003: CD001729.
   Google Scholar
• Bandi V, Apicella MA, Mason E, et al. Non-typeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am J Respir Crit Care Med 2001; 164: 2114–9
   PubMed Web of Science ®Google Scholar
• Bandi V, Jakubowycz M, Kinyon C, et al. Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeable Haemophilus influenzae. FEMS Immunol Med Microbiol 2003; 37: 69–75
   PubMed Web of Science ®Google Scholar
• Lagerstrom F, Bader M, Foldevi M, Fredlund H, Nordin-Olsson I, Holmberg H. Microbiological aetiology in clinically diagnosed community-acquired pneumonia in primary care in Orebro, Sweden. Clin Microbiol Infect 2003; 9: 645–52
   PubMed Web of Science ®Google Scholar
• Dabernat H, Plisson-Sauné M, Delmas C, et al. Haemophilus influenzae carriage in children attending French day-care centres: a molecular epidemiological study. Antimicrobial Agents and Chemotherapy 2003; 41: 1664–72
   Google Scholar
• Jain A, Kumar P, Awasthi S. High nasopharyngeal carriage of drug resistant Streptococcus pneumoniae and Haemophilus influenzae in North Indian schoolchildren. Trop Med Int Health 2005; 10: 234–9
   PubMed Web of Science ®Google Scholar
• Koeth LM, Jacobs MR, Good CE, et al. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg) against 9172 respiratory isolates collected worldwide in 2000. Int J Infect Dis 2004; 8: 362–73
   PubMedGoogle Scholar
• Agarwal G, Awasthi S, Kabra SK, Kaul A, Singhi S, Walter SD. Three-d versus 5-d treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomized controlled trial. Br Med J 2004; 328: 791
   PubMed Web of Science ®Google Scholar
• Addo-Yobo E, Chisaka N, Hassan M, et al. Oral amoxicillin versus injectable penicillin for severe pneumonia in children aged 3 to 59 months: a randomized multicentre equivalency study. Lancet 2004; 364: 1141–8
   PubMed Web of Science ®Google Scholar
• Pakistan Multicentre Amoxicillin Short Course Therapy (MASCOT) pneumonia study group. Clinical efficacy of 3 d versus 5 d of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. Lancet 2002; 360: 835–41
   PubMedGoogle Scholar
• Straus WL, Qazi SA, Kundi Z, Nomani NK, Schwartz B. Antimicrobial resistance and clinical effectiveness of cotrimoxazole versus amoxicillin for pneumonia among children in Pakistan: randomized controlled trial. Pakistan Co-trimoxazole Study Group. Lancet 1998; 352: 270–4
   PubMed Web of Science ®Google Scholar
• CATCHUP Study Group. Clinical efficacy of co-trimoxazole versus amoxicillin twice daily for treatment of pneumonia: a randomized controlled clinical trial in Pakistan. Arch Dis Child 2002; 86: 113–8
   PubMed Web of Science ®Google Scholar
• Petitpretz P, Chidiac C, Soriano F, Garau J, Stevenson K, Rouffiac E. The efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate 2000/125 mg, twice daily, versus oral amoxicillin-clavulanate 1000/125 mg, 3 times daily, for the treatment of bacterial community-acquired pneumonia in adults. Int J Antimicrob Agents 2002; 20: 119–29
   PubMed Web of Science ®Google Scholar
• Sehti S, Breton J, Winne B. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2000/125 mg twice daily for 5 d versus amoxicillin-clavulanate at 875/125 mg twice daily for 7 d in the treatment of acute exacerbations of chronic bronchitis. Antimicrob Agents Chemother 2005; 49: 153–60
   PubMedGoogle Scholar
• Piroth L, Martin L, Coulon A, et al. Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics. Antimicrob Agents Chemother 1999; 43: 2484–92
   PubMedGoogle Scholar
• Etienne M, Croisier D, Charles PE, et al. Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits. J Infect Dis 2004; 190: 1472–5
   PubMedGoogle Scholar
• Croisier D, Etienne M, Piroth L, et al. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. J Antimicrob Chemother 2004; 54: 640–7
   PubMed Web of Science ®Google Scholar
• Croisier D, Etienne M, Bergoin E, et al. Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. Antimicrob Agents Chemother 2004; 48: 1699–707
   PubMed Web of Science ®Google Scholar
• Croisier D, Chavanet P, Lequeu C, et al. Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. J Antimicrob Chemother 2002; 50: 349–60
   PubMed Web of Science ®Google Scholar
• Cantoni L, Wenger A, Glauser MP, Bille J. Comparative efficacy of amoxicillin-clavulanate, cloxacillin, and vancomycin against methicillin-sensitive and methicillin-resistant Staphylococcus aureus endocarditis in rats. J Infect Dis. 1989; 159: 989–93
   PubMedGoogle Scholar
• Kaye CM, Allen A, Perry S, et al. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clin Ther 2001; 23: 578–84
   PubMed Web of Science ®Google Scholar
• Berry V, Hoover J, Singley C, Woodnutt G. Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae. Antimicrob Agents Chemother 2005; 49: 908–15
   PubMedGoogle Scholar
• Clark C, Kosowska K, Bozdogan B, et al. In vitro selection of resistance in Haemophilus influenzae by 4 quinolones and 5 beta-lactams. Diagn Microbiol Infect Dis 2004; 49: 31–6
   PubMedGoogle Scholar
• Brook I, Gober AE. Antimicrobial resistance in the nasopharyngeal flora of children with acute maxillary sinusitis and maxillary sinusitis recurring after amoxicillin therapy. J Antimicrob Chemother 2004; 53: 399–402
   PubMedGoogle Scholar
• Brook I, Gober AE. Effect of amoxicillin and co-amoxiclav on the aerobic and anaerobic nasopharyngeal flora. J Antimicrob Chemother 2002; 49: 689–92
   PubMedGoogle Scholar
• Brook I, Gober AE. Antimicrobial resistance in the nasopharyngeal flora of children with acute otitis media and otitis media recurring after amoxicillin therapy. J Med Microbiol 2005; 54: 83–5
   PubMed Web of Science ®Google Scholar
• Ball P, Baquero F, Cars O, et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002; 49: 31–40
   PubMed Web of Science ®Google Scholar
• Craig, WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1–10; quiz 11–2.
   PubMed Web of Science ®Google Scholar
• Lowdin E, Cars O, Odenholt I. Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens including a pharmacokinetically enhanced formulation. Clin Microbiol Infect 2002; 8: 646–53
   PubMedGoogle Scholar
• MacGowan AP, Noel AR, Rogers CA, Bowker KE. Antibacterial effects of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae strains for which MICs are high, in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 2004; 48: 2599–603
   PubMed Web of Science ®Google Scholar
• Fogarty CM, Cyganowski M, Palo WA, Hom RC, Craig WA. A comparison of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of community-acquired pneumonia: a multicentre, prospective, randomized, investigator-blinded, parallel-group study. Clin Ther 2002; 24: 1854–70
   PubMed Web of Science ®Google Scholar
• Calver AD, Walsh NS, Quinn PF, et al. Dosing of amoxicillin/clavulanate given every 12 h is as effective as dosing every 8 h for treatment of lower respiratory tract infection. Lower Respiratory Tract Infection Collaborative Study Group. Clin Infect Dis 1997; 24: 570–4
   PubMed Web of Science ®Google Scholar
• Garau J, Twynholm M, Garcia-Mendez E, Siquier B, Rivero A. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, 3 times daily, in the treatment of community-acquired pneumonia in European adults. J Antimicrob Chemother 2003; 52: 826–36
   PubMedGoogle Scholar
• Dabernat H, Seguy M, Faucon G, Delmas C. Epidemiology of Haemophilus influenzae strains identified in 2001 in France, and assessment of their susceptibility to beta-lactams. Med Mal Infect 2004; 34: 97–101
   PubMedGoogle Scholar
• Perez-Trallero E, Garcia-de-la-Fuente C, Garcia-Rey C, et al. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005; 49: 1965–72
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Bajaksouzian S, Windau A, et al. Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998–2001 U S Surveillance Study. Clin Lab Med 2004; 24: 503–30
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229–46
   PubMed Web of Science ®Google Scholar